PDS Biotech (PDSB) - חוב להון עצמי

PDS Biotechnology develops innovative vaccines by stimulating the body's T-cell response to combat tumors. The business relies on strict FDA oversight and patent protection for its developments amidst intense lobbying. The current total debt-to-equity ratio is 0.00. The price history on the chart below demonstrates the financial dynamics of the company, which specializes in cancer immunotherapy.

This indicator determines the degree of financial leverage by comparing total liabilities to equity to assess the business's resilience to credit risks. By analyzing the D/E ratio (total debt to equity), an investor can see the balance between borrowed and owned resources, which is critically important for PDS Biotechnology (PDSB) when financing laboratory robotization and implementing AI into vaccine development.